US 12,145,960 B2
Nucleotide analogues
Ronald Graham, Carlsbad, CA (US); Olga Adelfinskaya, San Marcos, CA (US); Megha Cila, San Diego, CA (US); Rodrigo Rodriguez, San Diego, CA (US); Abrehet Abdu, San Diego, CA (US); and Eli N. Glezer, Del Mar, CA (US)
Assigned to Singular Genomics Systems, Inc., San Diego, CA (US)
Appl. No. 17/287,255
Filed by Singular Genomics Systems, Inc., La Jolla, CA (US)
PCT Filed Oct. 24, 2019, PCT No. PCT/US2019/057842
§ 371(c)(1), (2) Date Apr. 21, 2021,
PCT Pub. No. WO2020/086834, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/841,146, filed on Apr. 30, 2019.
Claims priority of provisional application 62/789,877, filed on Jan. 8, 2019.
Claims priority of provisional application 62/750,552, filed on Oct. 25, 2018.
Prior Publication US 2023/0028359 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 19/14 (2006.01); C07H 19/10 (2006.01); C07H 19/20 (2006.01); C12Q 1/68 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/6876 (2018.01)
CPC C07H 19/14 (2013.01) [C07H 19/10 (2013.01); C07H 19/20 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6876 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A compound having the formula:

OG Complex Work Unit Chemistry
wherein,
BP is a nucleobase;
R1P is hydrogen, or 5′-nucleoside protecting group, or —OR1P is a monophosphate, or polyphosphate;
R3P is hydrogen or —OR3AP; wherein R3AP is hydrogen or a polymerase-compatible cleavable moiety;
L1P is a substituted methylene, wherein L1P is substituted with a haloalkyl, or substituted or unsubstituted heteroalkyl; and
R6P is unsubstituted alkyl.